Search results
Found 641 matches for
An internationally recognised centre of excellence for biomedical and clinical research and teaching
Serotonin changes how people learn and respond to negative information
9 August 2024
Increasing serotonin can change how people learn from negative information, as well as improving how they respond to it, according to a new study published in the leading journal Nature Communications.
Proteins carried in the blood offer new insights into ageing and age-related disease risk
8 August 2024
Researchers at Nuffield Department of Population Health have found that proteins carried in the blood offer new insights into ageing and how it influences our risk of developing age-related diseases such as dementia, heart disease, and liver disease later in life. The study is published in Nature Medicine.
Study reveals previously unknown genetic causes of colorectal cancer
8 August 2024
A pioneering study, led by UK universities, including the University of Oxford, The Institute of Cancer Research, London, the University of Manchester and the University of Leeds, has provided the most comprehensive analysis to date of the genetic makeup of colorectal cancer (CRC).
Exploring the health impacts of climate change
5 August 2024
In a new study, published in Nature Reviews Endocrinology, endocrinologists and researchers from the Nuffield Department of Women’s & Reproductive Health (NDWRH) at the University of Oxford, the London School of Hygiene & Tropical Medicine, the William Harvey Research Institute (WHRI) at Queen Mary University of London and the National University of Singapore have emphasised the critical need for further research into the effects of heat exposure on the endocrine system.
Active Surveillance Patients International honours ProtecT Trial for pioneering research demonstrating the safety of active surveillance
5 August 2024
The ProtecT Trial has been named the 2024 recipient of the Active Surveillance Patients International (ASPI) Special Award for game-changing research in the development of the Active Surveillance approach to managing low-risk prostate cancer.
Long-term cognitive and psychiatric effects of COVID-19 revealed in new study
1 August 2024
Many people who were hospitalised with COVID-19 continue to have cognitive and psychiatric problems even two to three years post-infection, according to a new study published in Lancet Psychiatry.
The scale of Long COVID: New study highlights the widespread impact
1 August 2024
A comprehensive state-of-the-art review published today in The Lancet has revealed the widespread impact of Long COVID, providing crucial insights into the condition's biological mechanisms and outlining key areas for future research.
The Oxford students at the forefront of the fight against microbial resistance
30 July 2024
Antimicrobial resistance (AMR) is one the most pressing challenges facing the world today. Common infections that were once easily treated by antibiotics are becoming life-threatening again. By 2050 it is predicted that over 10 million deaths will be caused by drug-resistant infections every year.
New Oxford quantum hub to tackle key challenges in quantum technologies
26 July 2024
Today, the UK Government has announced the launch of five new research hubs to develop quantum technologies in areas ranging from healthcare and computing to national security and critical infrastructure. One of the hubs will be led by the University of Oxford, and aims to develop the technologies needed for the UK to play a key role in the development of quantum computers - a market estimated to be worth $1.3 trillion by 2035.
New shingles vaccine could reduce risk of dementia
26 July 2024
The new recombinant shingles vaccine ‘Shingrix’ is associated with a reduced risk of dementia compared to an earlier shingles vaccine, according to a major new study published in Nature Medicine. It is also more protective than vaccines against other infections.
Future of Oxford lactation research centre secured with £9.12 million donation
24 July 2024
A £9.12 million gift from the Family Larsson-Rosenquist Foundation has endowed an Oxford University research centre investigating the role of hormones in human milk production.
The Oxford Respiratory Trials Unit awarded £2.8m to study treatment for pleural infection
23 July 2024
The Oxford Respiratory Trials Unit (ORTU) at the Nuffield Department of Medicine has been awarded a £2.8 million grant from the National Institute for Health and Care Research Health Technology Assessment (NIHR HTA) to conduct the MIST4 study.
Shorter life expectancy during COVID-19 for India’s marginalised
23 July 2024
A new paper published in Science Advances finds that life expectancy in India was 2.6 years lower in 2020 than 2019, with women and marginalised social groups suffering the greatest declines.
Three hospital trusts participating in an Oxford-led study evaluating AI software for diagnosing prostate cancer in clinical settings
22 July 2024
Oxford University Hospitals (OUH) NHS Foundation Trust, North Bristol NHS Trust, and University Hospitals Coventry and Warwickshire (UHCW) NHS Trust are evaluating a new Artificial Intelligence (AI) diagnostic system that could help improve prostate cancer diagnosis.
Apollo Therapeutics and Oxford University enter into drug discovery and development collaboration
22 July 2024
The University of Oxford and Apollo Therapeutics, a portfolio biopharmaceutical company, announce the signing of a drug discovery and development collaboration aimed at translating breakthroughs made by biomedical researchers at Oxford.
Centre to address global epilepsy challenges launched at Oxford’s Wolfson College
22 July 2024
The University of Oxford is launching The Centre for Global Epilepsy to address the global burden of epilepsy, particularly in lower-income countries.
Yellowstone Biosciences spinout launches to advance cutting-edge cancer therapies
15 July 2024
Yellowstone Biosciences, a biotechnology spinout, has launched to pioneer new cancer treatments using advanced T-cell therapies based on ground-breaking research from the MRC Weatherall Institute of Molecular Medicine at University of Oxford.
Côte d’Ivoire makes history as first nation to deploy R21/Matrix-M™ Malaria Vaccine
15 July 2024
Today marks the official rollout of the new R21/Matrix-M™ malaria vaccine - co-developed by the University of Oxford and Serum Institute of India, leveraging Novavax’s Matrix-M™ adjuvant technology. In a historic step in the battle to beat malaria, the first official vaccination is due to take place in Abidjan, Côte d’Ivoire, this morning and will be subsequently rolled-out in 38 districts across the country.
COVID-19 phone apps shown to provide real-time information on the spread of infectious diseases
12 July 2024
Researchers analysing data from mobile phone apps used during the COVID-19 pandemic found that digital contact tracing provides rich insights into epidemic dynamics with unprecedented resolution and speed, revealing how transmission varied by day of the week, gatherings during the 2021 Christmas period, and the UEFA Euro football tournament in July 2021
Major UK study reveals shifting trends and persistent challenges in heart disease over the last 20 years
27 June 2024
A groundbreaking new study has shed light on how the landscape of heart disease has evolved in the UK over the past two decades. Researchers analyzed electronic health records from the Clinical Practice Research Datalink (CPRD GOLD and Aurum), encompassing a representative cohort of 22 million individuals. This included 1,650,052 people newly diagnosed with at least one cardiovascular disease (CVD) between 2000 and 2019, with an average age of 70.5 years, of whom 48% were women.